Medication info

Twin Beta-Al Tablet 80/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationApproval withdrawn
Ingredient · strength
Telmisartan›Strength being verifiedAmlodipine Besylate›Strength being verifiedRosuvastatin Calcium›Strength being verified
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Bright pink oval film-coated tablets
Packaging
30 tablets (10 tablets x 3) / PTP
Approval status
Approval withdrawn

MFDS item code 201803889 · Approved 2018.10.02

This product's status changed to Approval withdrawn on 2023.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression and cardiovascular disease risk
Who uses it
Adults
Adult dosage
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination and rosuvastatin as separate medicines may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended to adjust the dose using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, switching directly to the telmisartan/amlodipine combination may be considered when blood pressure is not controlled with the individual components, as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The starting dose is 5 milligrams once daily. If greater LDL cholesterol reduction is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less; however, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose in patients predisposed to myopathy is 5 milligrams. The 40 milligrams dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease.
View approved original text

This medication is used for patients with essential hypertension whose blood pressure is difficult to control using a combination of telmisartan and amlodipine, while rosuvastatin is used as an adjunct when dietary therapy and exercise are ineffective for hypercholesterolemia and various lipid disorders. Furthermore, rosuvastatin helps slow the progression of atherosclerosis and reduces the risk of stroke, myocardial infarction, and vascular interventions in certain patients at high risk of cardiovascular diseases. Therefore, this medication is used to improve cardiovascular health by managing hypertension and hyperlipidemia.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. Patients taking the telmisartan/amlodipine combination and rosuvastatin as separate medicines may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination It is recommended to adjust the dose using the individual components (amlodipine or telmisartan) before administering the telmisartan/amlodipine combination. However, switching directly to the telmisartan/amlodipine combination may be considered when blood pressure is not controlled with the individual components, as follows. - 40/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or telmisartan 40 milligrams. - 80/5 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or this medicine 40/5 milligrams. - 40/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams. - 80/10 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or this medicine 40/10 milligrams. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 milligrams in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, initiate treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The starting dose is 5 milligrams once daily. If greater LDL cholesterol reduction is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less; however, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score above 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose in patients predisposed to myopathy is 5 milligrams. The 40 milligrams dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication may cause serious harm to the fetus during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with allergies to the ingredients in this medicine or similar drugs, those with specific liver or kidney diseases, and patients with severe heart conditions should not take this medication. Patients with hypertension, hyperlipidemia, weak liver or kidney function, the elderly, and those with certain muscle diseases should take this medication with special caution and require regular testing. If muscle pain, muscle weakness, severe fatigue, or reduced urine output occurs during the treatment, consult a doctor immediately. There may be interactions if taken with other medications, so it is essential to inform the healthcare provider of any current medications, especially when combined with specific antibiotics, immunosuppressants, or antihypertensives. This medication could affect the liver and kidneys, hence regular liver and kidney function tests are required. Caution is necessary when driving or operating machinery as dizziness or drowsiness may occur. In case of overdose, symptoms like hypotension, dizziness, and irregular heartbeats may appear, requiring immediate medical attention. Safety has not been established in children, so its use is not recommended, and it should be kept out of reach of children.

Side effects

Viral upper respiratory tract infection, dyspnea, anal bleeding, dyspepsia, atopic dermatitis, peripheral edema, peripheral edema, dizziness, orthostatic hypotension, low back pain, headache, hepatocellular carcinoma, cerebral infarction, congestive heart failure, musculoskeletal pain, neck pain, nasopharyngitis, upper abdominal discomfort, upper abdominal pain, positional vertigo, dysuria, rhinitis, oropharyngeal discomfort, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina pectoris, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, vertigo, sensory abnormalities, involuntary muscle contractions, sensory loss, flatulence, constipation, gastritis, vomiting, dry mouth, hemorrhoids, gastroenteritis, enteritis, gastroesophageal reflux, toothache, nonspecific gastrointestinal disease, gout, hypercholesterolemia, diabetes, arthritis, arthralgia, leg numbness, anxiety, depression, irritability, infection, fungal infection, abscess, otitis media, asthma, bronchitis, rhinitis, epistaxis, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, cerebrovascular disease, visual disturbances, conjunctivitis, ear pain, angioedema, erectile dysfunction, myasthenia, thrombocytopenia, increased uric acid, liver dysfunction, liver disease, acute renal failure, anemia, CPK elevation, anaphylactic reaction, tendon pain, rhabdomyolysis, headache, edema, dizziness, flushing, palpitations, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reaction, burning sensation, lethargy, stiffness, weight gain, weight loss, arthrosis, muscle cramps, sexual dysfunction, insomnia, irritability, abnormal dreams, anxiety, depersonalization, dyspnea, angioedema, erythema multiforme, papular rash, diplopia, eye pain, nocturia, dry mouth, increased sweating, hyperglycemia, thirst, leukopenia, purpura, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, myasthenia gravis, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that blocks light. Additionally, it is important to store the medication at a temperature between 1 and 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Bright pink oval film-coated tablets

Package unit

30 tablets (10 tablets x 3) / PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.